Association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and risk of rheumatic heart

Hsiang-Tai Chou1, Chang-Hai Tsai, Fuu-Jen Tsai

  • 1Division of Cardiology, Department of Medicine, China Medical University Hospital, Taichung 404, Taiwan, ROC.

Japanese Heart Journal
|January 19, 2005
PubMed

Insights

Genetic variations in the angiotensin I-converting enzyme (ACE) gene, specifically the I/D polymorphism, are linked to an increased risk of rheumatic heart disease (RHD) in Taiwan Chinese. The G2350A polymorphism showed no association with RHD.

Area of Science:

  • Cardiovascular Genetics
  • Rheumatic Heart Disease Pathogenesis
  • Molecular Biology

Background:

  • Rheumatic heart disease (RHD) involves valve scarring and myocyte destruction, potentially influenced by angiotensin I-converting enzyme (ACE).
  • ACE genetic variants' role in RHD pathogenesis remains understudied in specific populations.

Purpose of the Study:

  • To investigate the association between ACE gene insertion/deletion (I/D) and G2350A polymorphisms and RHD in Taiwan Chinese.
  • To determine if ACE gene variants contribute to RHD risk in this population.

Main Methods:

  • A case-controlled study involving 115 RHD patients and 100 healthy controls.
  • Polymerase chain reaction-based restriction analysis to identify ACE gene I/D and G2350A polymorphisms.
  • Statistical analysis of genotype and allelic frequencies and odds ratios.

Main Results:

  • Significant differences in ACE I/D genotype (P=0.02) and allelic frequencies (P=0.04) were observed between RHD patients and controls.
  • The ACE II genotype (OR=2.12) and I allele (OR=1.50) were associated with an increased risk of RHD.
  • No significant association was found for the ACE G2350A polymorphism (P=0.90).

Conclusions:

  • The ACE I/D gene polymorphism plays a role in determining RHD risk among Taiwan Chinese.
  • Higher frequencies of ACE II genotype and I allele support the involvement of ACE I/D variants in RHD susceptibility.

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
282
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
476
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
426
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.3K
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.1K